Vulvar Cancer: Histopathologic Considerations and Nuances to Management: Vulvar cancer considerations and nuances.

KeyWords

Journal

Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279

Informations de publication

Date de publication:
27 Aug 2024
Historique:
received: 01 07 2024
revised: 15 07 2024
accepted: 17 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: aheadofprint

Résumé

Vulvar cancer, though rare, poses significant challenges in diagnosis and treatment due to its histopathological complexities and nuances. This paper reviews key aspects of the management of vulvar cancer, focusing on histopathological diagnosis, margin status interpretation, lymph node involvement assessment, and ongoing clinical trials.

Identifiants

pubmed: 39209108
pii: S1879-8500(24)00207-8
doi: 10.1016/j.prro.2024.07.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The following authors have disclosed relationships/activities/interests related to the content of this manuscript: S Bedell: $1000 grant for pilot project involving RNA sequencing machine for pilot project of evolutionary mechanisms in endometrial cancer cell lines - Cleveland Society for Obstetrics and Gynecology (CLESOG). C DeCesaris: Employment at the University of Utah; Breast and Gynecologic Cancers Center IIT Grant – SAVE Trial; UG1 grant funding for the NRG 2024 Winter and Summer meetings. G Suneja: American Brachytherapy Society GYN Brachy School 2024; Radiation Oncology Institute, Vice-President of the Board of Trustees. L Burt: Investigator initiated grants for the Reiki-Brachy trial, Med-RT trial, SAVE in Ghana trial and SRS dose escalation trial; Mock oral board examiner honorarium $750 (March 2023), Mock ACGME review for UC Irvine 12/2022 $1000; Leadership - oral board examiner, themednet deputy editor. D Gaffney: Merck, DSMC Chair.

Auteurs

Lindsay Burt (L)

University of Utah Health, Huntsman Cancer Institute, Department of Radiation Oncology, Salt Lake City, Utah, USA. Electronic address: Lindsay.burt@hci.utah.edu.

Elke Jarboe (E)

Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Dave Gaffney (D)

University of Utah Health, Huntsman Cancer Institute, Department of Radiation Oncology, Salt Lake City, Utah, USA.

Gita Suneja (G)

University of Utah Health, Huntsman Cancer Institute, Department of Radiation Oncology, Salt Lake City, Utah, USA.

Cristina DeCesaris (C)

University of Utah Health, Huntsman Cancer Institute, Department of Radiation Oncology, Salt Lake City, Utah, USA.

Sabrina Bedell (S)

University of Utah Health, Huntsman Cancer Institute, Department of Obstetrics and Gynecology, Salt Lake City, UT, USA.

Jeffrey Brower (J)

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Radiation Oncology Associates-New England, Manchester, New Hampshire.

Classifications MeSH